Home pageRDY • NYSE
add
Dr. Reddy's Laboratories
14,44Â $
After Hours:(0,90%)+0,13
14,57Â $
Data e ora chiusura: 16 mag, 16:36:01 GMT-4 · USD · NYSE · Disclaimer
Chiusura precedente
14,39Â $
Intervallo giornaliero
14,27Â $ - 14,46Â $
Intervallo annuale
12,26Â $ - 16,89Â $
Cap di mercato
12,09Â Mld USD
Volume medio
2,43Â Mln
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(INR) | mar 2025info | Variazione Y/Y |
---|---|---|
Entrate | 85,06Â Mld | 20,09% |
Spese di gestione | 30,40Â Mld | 13,94% |
Utile netto | 15,94Â Mld | 21,95% |
Margine di profitto netto | 18,74 | 1,57% |
Utili per azione | 19,84 | 27,69% |
EBITDA | 21,42Â Mld | 23,29% |
Aliquota fiscale effettiva | 20,85% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(INR) | mar 2025info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 57,91Â Mld | -28,92% |
Totale attivo | 492,99Â Mld | 27,22% |
Totale passivo | 155,82Â Mld | 45,67% |
Patrimonio netto totale | 337,17 Mld | — |
Azioni in circolazione | 833,19 Mln | — |
Prezzo/valore contabile | 0,04 | — |
Redditività dell'attivo | 8,66% | — |
Rendimento sul capitale | 11,14% | — |
Flusso di cassa
Flusso di cassa netto
(INR) | mar 2025info | Variazione Y/Y |
---|---|---|
Utile netto | 15,94Â Mld | 21,95% |
Liquidità di esercizio | 22,00 Mld | 90,94% |
Contanti da investimenti | -6,24Â Mld | 44,99% |
Contanti da finanziamenti | -14,43Â Mld | -2.606,57% |
Flusso di cassa netto | 1,56Â Mld | 464,72% |
Flusso di cassa libero | 7,69Â Mld | -3,61% |
Informazioni
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Fondazione
1984
Sito web
Dipendenti
27.048